UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.

Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.

University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.

A year after reportedly hiring banks for an IPO, multi-corporate-backed Velodyne has instead chosen a reverse merger to list on the New York Stock Exchange.

Comcast, McKesson, Humana and Independence Health all scored exits as the health benefits services provider floated in an upscaled offering.

SoftBank, XL Catlin, Allianz and Alphabet-backed casualty and property insurance provider Lemonade priced the initial public offering above its range.

QuantumCTek has filed for a $102m initial public offering, more than a decade after being spun out of University of Science and Technology of China.

The Lithia Motors, BMW and Alliance Ventures-backed automotive e-commerce marketplace is set to go public through a reverse merger with Insurance Acquisition.

The UC Berkeley-linked cell biology technology provider has raised about $215m in venture funding.

SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.